The role of sodium–glucose co-transporter 2 inhibitors in myocardial infarction: available evidence and future perspectives

Abstract

There is an unmet need for new treatment options for patients with acute myocardial infarction (AMI) as progress in patients’ outcomes has plateaued over the past 15 years. Sodium–glucose co-transporter 2 (SGLT2) inhibitors have demonstrated cardio-renal benefits in various disease states, encompassing diabetes mellitus, chronic kidney disease, and heart failure. Experimental studies further support their use in AMI, demonstrating beneficial effects in animal models by reducing infarct size and mitigating adverse cardiac remodelling. Recently, two clinical trials have been published thus paving the way for a new field to explore. This paper briefly outlines the available evidence and future perspectives regarding the use of SGLT2 inhibitors in this clinical scenario.